OrphoMed

OrphoMed

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc., with participation from other prior investors: Pappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.

The capital will be used to advance the clinical development of OrphoMed's lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
OrphoMed funding round, May 2017
39,000,000
May 2017
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.